Literature DB >> 11232945

Impact of boost technique on outcome in early-stage breast cancer patients treated with breast-conserving therapy.

R C Frazier1, L L Kestin, V Kini, A A Martinez, P Y Chen, K L Baglan, F A Vicini.   

Abstract

We reviewed our institution's experience treating early-stage breast cancer patients with breast-conserving therapy (BCT) to determine the impact of boost technique on outcome. A total of 552 patients with stage I and II breast cancer were managed with BCT. All patients were treated with a partial mastectomy and radiation therapy (RT). RT consisted of 45 Gy to 50 Gy external beam irradiation to the whole breast followed by a boost to the tumor bed using either electrons (232 patients), photons (15 patients), or an interstitial implant (316 patients). Local control and cosmetic outcome was compared among three patient groups based on the type of boost used. Forty-one patients had a recurrence of cancer in the treated breast for 5-, 10-, and 13-year actuarial local recurrence rates of 2.8%, 7.5%, and 11.2%, respectively. There were no significant differences in the local recurrence rates or cosmetic outcome using electrons, photons, or an interstitial implant. On multivariate analysis, only young age and margin status were associated with local recurrence. Stage I and II breast cancer patients undergoing BCT can be effectively managed with electron, photon, or interstitial implant boost techniques. Long-term local control and cosmetic outcome are excellent regardless of which boost technique is used.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11232945     DOI: 10.1097/00000421-200102000-00004

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  7 in total

1.  Ten-year results of a phase II study with a single fraction of high-dose-rate brachytherapy (FAST-boost) after whole breast irradiation in invasive breast carcinoma.

Authors:  José Luis Guinot; M Isabel Tortajada; María Carrascosa; Vicente Crispín; Ana Otero; Belén Ríos; Eleonor Rivin; Miguel Santos; Pablo Soler; Leoncio Arribas
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

Review 2.  The role of boost irradiation in the conservative treatment of stage I-II breast cancer.

Authors:  C Polgár; J Fodor; T Major; Z Orosz; G Németh
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

3.  [Single fraction boost with high dose rate interstitial brachytherapy in conservative treatment of breast carcinoma].

Authors:  Inmaculada Beato Tortajada; Jose Luis Guinot Rodríguez; Leoncio Arribas Alpuente; Manuel Aguayo Martos; María Carrascosa Pérez; Maribel Tortajada Azcutia; Pedro Pablo Escolar Pérez; María Maroñas Martín; Marisa Chust Vicente; José Luis Mengual Cloquell; Carmen Pesudo Ayet; Manuel Casaña Giner
Journal:  Clin Transl Oncol       Date:  2005-10       Impact factor: 3.405

4.  The use of an interstitial boost in the conservative treatment of breast cancer: how to perform it routinely in a radiotherapy department.

Authors:  Cristina Gutiérrez; Dina Najjari; Evelyn Martínez; Saray Botella; Arantxa Eraso; Francisco Pino; Ferran Moreno; Joan Pera; Ferran Guedea
Journal:  J Contemp Brachytherapy       Date:  2014-11-17

5.  Tumor bed boost in breast cancer: Brachytherapy versus electron beam.

Authors:  Sanjoy Roy; Tapas Maji; Prabir Chaudhuri; Debarshi Lahiri; Jaydip Biswas
Journal:  Indian J Med Paediatr Oncol       Date:  2013-10

6.  Pulsed-dose-rate peri-operative brachytherapy as an interstitial boost in organ-sparing treatment of breast cancer.

Authors:  Krystyna Serkies; Janusz Jaśkiewicz; Rafał Dziadziuszko; Jacek Jassem
Journal:  J Contemp Brachytherapy       Date:  2016-12-09

7.  Comparison of the Oncological Efficacy Between Intraoperative Radiotherapy With Whole-Breast Irradiation for Early Breast Cancer: A Meta-Analysis.

Authors:  Lin He; Jiejing Zhou; Yuhong Qi; Dongjie He; Canliang Yuan; Hao Chang; Qiming Wang; Gaiyan Li; Qiuju Shao
Journal:  Front Oncol       Date:  2021-12-17       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.